



**Oxford University Hospitals**  
NHS Foundation Trust

## **Financial Performance: Month 4 2019/20**

**Trust Board: 11<sup>th</sup> September 2019**

**TB2019.94**

Jason Dorsett: Chief Finance Officer

Prepared by: Jon Evans, Director of Finance



## Executive Summary


Income and Expenditure (I&E) position, excl PSF/MRET, is a year to date deficit of -£9.4m, £5.4m worse than plan. In-month I&E performance was a deficit of -£3.0m, £5.5m worse than plan.

The major drivers of year to date performance are as follows:

- +£4.3m one off items delivered earlier than planned
- +£7.3m released prior year accruals, £1.8m to offset to date over performance on the OCCG contract and £5.4m to the bottom line
- -£8.9m loss of activity due to the JR2 theatres refresh, case mix, urgent care blended payment and chemotherapy drugs
- -£3.6m undelivered reductions and continued increase in temporary staffing costs and undelivered improvements in productivity

Adjusting out one off (£4.3m) and non-specific prior year accrual releases (£5.4m), year to date performance is a deficit of -£19.1m or £15.2m worse than plan.

Cumulative Performance against NHSI Control Total (£m)



Area	Key Points	Actions
Income	<p>Income is -£8.5m worse than plan to date, due to:</p> <ul style="list-style-type: none"> <li>• <u>Commissioning Income</u> worse than plan by -£5.8m <ul style="list-style-type: none"> <li>- Release of prior year accruals following resolution of year end issues (+£4.8m)</li> <li>- JR2 theatres refresh, case mix and other activity (-£6.5m), backdated correction to chemotherapy drugs billing (-£1.6m), urgent care blended payment (-£0.8m) and contract penalties (-£0.4m)</li> <li>- By commissioner, the split is Specialised/NHSE (-£9.1m) and OCCG (+£2.2m)</li> <li>- Activity related commissioning income has improved (based on estimate) compared to previous months but still -£1.6m worse than plan in-month</li> </ul> </li> <li>• <u>Private, Overseas and Other Income</u> (-£1.7m) and R&amp;D, offset in expenditure (-£1.1m)</li> </ul>	<p>Review of elective capacity/activity post JR2 refresh completion in July</p> <p>Confirm impact of clinical coding audit in Vascular in month 4</p> <p>Carry out audits in Trauma, Paediatric Clinical Haematology and Neurosurgery</p> <p>Agree with OCCG the first estimate of in-year contract flexibility</p>
Expenditure	<p>Expenditure is -£1.7m worse than plan to date, due to:</p> <ul style="list-style-type: none"> <li>• <u>Pay</u>: -£5.4m worse than plan, including +£1.2m in R&amp;D, from continued increase in premium temporary staffing costs, undelivered productivity improvements and the cost of medical pay ward (£1.5m), backdated to April but accounted for in month</li> <li>• <u>Non-Pay</u>: +£3.7m better than plan, from unspent growth monies, release of contingency (+£1.3m) and release of prior year accruals (+£0.6m)</li> </ul>	<p>Non-clinical agency control paper to TME</p> <p>Review procurement non-pay savings plan by division</p> <p>Pause new approvals from business case reserve until Q2 reforecast completed (FD)</p>
One Off Items	+£4.3m higher than plan, with £4.3m of one off items reported to date.	Complete review of further one off items by end of Q2

## Executive Summary (Continued)

Area	Key Points	Actions
PSF	£7.0m reported based on Q1 financial performance being delivered. A further £0.8m, relating to 18/19 national performance, has been reported as directed by NHSI.	
Use of Resources Rating	Year to date performance gives a score, on the NHS Improvement Use of Resource metric for Finance, as 3, a deterioration from the score of 2 at the end of Q1. This is due to not meeting the financial plan at month 4 (score of 3). OUH score 3 out of 4 (lower is better) on liquidity, capital service cover, I&E margin and breaching the agency ceiling.	Premium cost reduction project includes a significant element on agency ceiling compliance
Cash	Cash was £72.8m at month end. This is £14.0m above the plan and £33.1m higher than the previous month end. £7.0m of the variance above plan is due to receiving quarterly education funding in advance, a change in policy. The balance due to timing of payments, which have unwound during August.	No action required
Capital	Capital expenditure year to date is £11.1m, £0.3m higher than plan. NHSE/I capital controls no longer in place	Complete review to create headroom for compliance priorities by end of Q2
Forecast	Normal Q2 reforecasting exercise being carried and will include the impact of JR2 theatres reopening, agency controls and other expected changes to trend. Board review/consideration on scale, risk and trade-offs in advance of Q2 financial performance submission to NHSI.	

## Summary Financial Performance

Financial Summary £000's	IN MONTH 4				YEAR TO DATE				FULL YEAR
	Plan	Actual	Variance	Variance %	Plan	Actual	Variance	Variance %	Plan
Income	94,993	91,307	(3,687)	-3.9%	363,451	354,908	(8,543)	-2.4%	1,095,517
Pay	(54,277)	(56,301)	(2,024)	-3.7%	(216,148)	(221,531)	(5,383)	-2.5%	(652,605)
Non-Pay	(33,593)	(33,606)	(13)	0.0%	(132,980)	(129,317)	3,663	2.8%	(400,537)
Underlying EBITDA	7,123	1,399	(5,724)	-80.4%	14,323	4,060	(10,263)	-71.7%	42,374
EBITDA %	7.5%	1.5%			3.9%	1.1%			3.9%
Underlying Surplus / (Deficit)	2,558	(2,983)	(5,541)	-216.6%	(3,938)	(13,678)	(9,739)	-247.3%	(12,422)
One Off Items	0	0	0	0.0%	0	4,327	4,327	0.0%	20,000
Control Total (Excl PSF/MRET)	2,558	(2,983)	(5,541)	-216.6%	(3,938)	(9,351)	(5,412)	-137.4%	7,578
PSF / MRET	2,285	1,330	(955)	-41.8%	8,424	8,309	(115)	-1.4%	30,290
Total (Including PSF/MRET)	4,843	(1,653)	(6,496)	-134.1%	4,486	(1,042)	(5,528)	-123.2%	37,868
Cash					58,788	72,778	13,990	23.8%	42,723
Capital (Gross)	3,195	2,683	(512)	-16.0%	11,442	11,107	(335)	-2.9%	58,232

Underlying financial performance is calculated by removing one off items from the adjusted (for NHSI performance reporting technical items) financial performance. No in-year items have been adjusted for.

Source: Finance Ledger

## Income and Expenditure: Subjective Analysis

I & E Subjective £000's	IN MONTH 4				YEAR TO DATE				FULL YEAR		
	Plan	Actual	Variance	Variance %	Plan	Actual	Variance	Variance %	Plan	Forecast	Variance
<b>Income</b>											
Commissioning Income	69,625	66,998	(2,627)	-3.8%	263,748	257,650	(6,098)	-2.3%	794,798		
Other Income	13,027	12,400	(626)	-4.8%	51,816	49,534	(2,282)	-4.4%	155,841		
Passthrough Drugs & Devices	11,450	11,081	(370)	-3.2%	44,441	44,775	334	0.8%	134,538		
PP, Overseas and RTA Income	892	828	(64)	-7.1%	3,446	2,950	(497)	-14.4%	10,340		
<b>Total Income</b>	<b>94,993</b>	<b>91,307</b>	<b>(3,687)</b>	<b>-3.9%</b>	<b>363,451</b>	<b>354,908</b>	<b>(8,543)</b>	<b>-2.4%</b>	<b>1,095,517</b>		
<b>Pay</b>											
Consultants and Medics	(18,244)	(20,250)	(2,006)	-11.0%	(73,228)	(76,539)	(3,311)	-4.5%	(219,366)		
Health Care Assistants & Support	(5,050)	(5,229)	(179)	-3.5%	(20,043)	(20,916)	(873)	-4.4%	(59,916)		
Nurse and Midwives	(15,241)	(15,118)	123	0.8%	(60,692)	(61,505)	(812)	-1.3%	(181,381)		
Other Staff	(7,932)	(8,523)	(591)	-7.4%	(32,927)	(33,853)	(926)	-2.8%	(104,388)		
Scientific, Thec., Therapeutic	(7,810)	(7,181)	628	8.0%	(29,258)	(28,718)	540	1.8%	(87,554)		
<b>Total Pay</b>	<b>(54,277)</b>	<b>(56,301)</b>	<b>(2,024)</b>	<b>-3.7%</b>	<b>(216,148)</b>	<b>(221,531)</b>	<b>(5,383)</b>	<b>-2.5%</b>	<b>(652,605)</b>		
<b>Non-Pay</b>											
Clinical negligence	(2,527)	(2,527)	(0)	0.0%	(10,106)	(10,117)	(10)	-0.1%	(30,319)		
Clinical Supplies & Services	(8,397)	(8,755)	(358)	-4.3%	(33,427)	(32,102)	1,325	4.0%	(100,304)		
Passthrough Drugs & Devices	(11,450)	(11,081)	370	3.2%	(44,441)	(44,775)	(334)	-0.8%	(134,538)		
Drugs	(244)	(280)	(36)	-14.8%	(2,913)	(448)	2,465	84.6%	(7,520)		
General Supplies & Services	(2,435)	(1,979)	456	18.7%	(9,741)	(8,064)	1,677	17.2%	(29,229)		
Internal Recharges	64	(0)	(64)	-100.0%	315	(0)	(315)	-100.0%	928		
Premises & Fixed Plant	(5,261)	(5,511)	(250)	-4.8%	(20,974)	(21,539)	(565)	-2.7%	(62,929)		
Other Expenditure	(3,344)	(3,474)	(130)	-3.9%	(11,691)	(12,271)	(580)	-5.0%	(36,626)		
<b>Total Non-Pay</b>	<b>(33,593)</b>	<b>(33,606)</b>	<b>(13)</b>	<b>0.0%</b>	<b>(132,980)</b>	<b>(129,317)</b>	<b>3,663</b>	<b>2.8%</b>	<b>(400,537)</b>		
<b>Underlying EBITDA</b>	<b>7,123</b>	<b>1,399</b>	<b>(5,724)</b>	<b>-80.4%</b>	<b>14,323</b>	<b>4,060</b>	<b>(10,263)</b>	<b>-71.7%</b>	<b>42,374</b>		
<b>Non-EBITDA (Incl Tech Adj)</b>	<b>(4,565)</b>	<b>(4,383)</b>	<b>183</b>	<b>4.0%</b>	<b>(18,262)</b>	<b>(17,738)</b>	<b>524</b>	<b>2.9%</b>	<b>(54,796)</b>		
<b>Underlying Surplus / (Deficit)</b>	<b>2,558</b>	<b>(2,983)</b>	<b>(5,541)</b>	<b>-216.6%</b>	<b>(3,938)</b>	<b>(13,678)</b>	<b>(9,739)</b>	<b>-247.3%</b>	<b>(12,422)</b>		

Source: Finance Ledger

### Income

- Commissioning income, including passthrough, is worse than plan by -£5.8m to date. This includes the full release of prior year accruals following resolution of year end issues, which give a benefit of £6.7m. £1.8m of this is to cover OCCG contract over performance, with the remaining £4.8m offsetting activity and case mix under performances.
- Other income variance includes -£1.2m from R&D, offset in expenditure.

### Pay

- Pay is worse than plan by £5.4m to date, with overspends due to continued increased use of temporary staffing and undelivered productivity improvements. In-month due to backdated medical pay award (-£1.5m) and agency spend.

### Non-Pay

- Non-Pay is better than plan by £3.7m to date, with clinical and general supplies and services costs lower due to unspent growth monies.

## Income and Expenditure: Divisional Overview

Divisional Overview (EBITDA) £000's	IN MONTH 4				YEAR TO DATE				FULL YEAR
	Plan	Actual	Variance	Variance %	Plan	Actual	Variance	Variance %	Plan
Income	7,132	6,920	(212)	-3.0%	26,417	26,038	(379)	-1.4%	80,970
Pay	(8,637)	(9,004)	(367)	-4.2%	(34,680)	(35,283)	(603)	-1.7%	(103,664)
Non-Pay	1,050	1,212	162	15.4%	4,192	3,993	(200)	-4.8%	12,574
<b>Total CSS</b>	<b>(454)</b>	<b>(871)</b>	<b>(417)</b>	<b>-91.9%</b>	<b>(4,070)</b>	<b>(5,252)</b>	<b>(1,182)</b>	<b>-29.0%</b>	<b>(10,120)</b>
Income	21,728	21,193	(535)	-2.5%	83,599	80,234	(3,366)	-4.0%	251,565
Pay	(11,193)	(11,213)	(20)	-0.2%	(43,239)	(43,846)	(608)	-1.4%	(129,259)
Non-Pay	(4,583)	(5,177)	(594)	-13.0%	(20,472)	(20,192)	280	1.4%	(61,423)
<b>Total MRC</b>	<b>5,952</b>	<b>4,803</b>	<b>(1,149)</b>	<b>-19.3%</b>	<b>19,888</b>	<b>16,195</b>	<b>(3,693)</b>	<b>-18.6%</b>	<b>60,883</b>
Income	29,016	28,044	(972)	-3.4%	109,571	105,192	(4,379)	-4.0%	330,901
Pay	(13,301)	(14,380)	(1,079)	-8.1%	(53,126)	(55,518)	(2,392)	-4.5%	(159,165)
Non-Pay	(8,146)	(8,020)	126	1.6%	(32,255)	(31,511)	743	2.3%	(96,795)
<b>Total NOTSSCaN</b>	<b>7,569</b>	<b>5,644</b>	<b>(1,925)</b>	<b>-25.4%</b>	<b>24,190</b>	<b>18,162</b>	<b>(6,028)</b>	<b>-24.9%</b>	<b>74,941</b>
Income	26,902	26,895	(6)	0.0%	103,193	102,544	(649)	-0.6%	309,715
Pay	(11,101)	(11,934)	(833)	-7.5%	(44,706)	(47,506)	(2,800)	-6.3%	(133,631)
Non-Pay	(8,944)	(9,428)	(484)	-5.4%	(36,073)	(36,851)	(778)	-2.2%	(108,282)
<b>Total SuWOn</b>	<b>6,856</b>	<b>5,533</b>	<b>(1,323)</b>	<b>-19.3%</b>	<b>22,414</b>	<b>18,187</b>	<b>(4,228)</b>	<b>-18.9%</b>	<b>67,802</b>
<b>Clinical Divisions</b>	<b>19,923</b>	<b>15,109</b>	<b>(4,814)</b>	<b>-24.2%</b>	<b>62,422</b>	<b>47,291</b>	<b>(15,131)</b>	<b>-24.2%</b>	<b>193,506</b>
Income	3,791	4,554	763	20.1%	15,870	15,340	(530)	-3.3%	36,596
Pay	(5,752)	(6,074)	(323)	-5.6%	(23,124)	(23,948)	(823)	-3.6%	(69,141)
Non-Pay	(13,191)	(13,480)	(289)	-2.2%	(52,850)	(53,470)	(620)	-1.2%	(158,540)
<b>Corporate Divisions</b>	<b>(15,151)</b>	<b>(15,000)</b>	<b>151</b>	<b>1.0%</b>	<b>(60,104)</b>	<b>(62,077)</b>	<b>(1,973)</b>	<b>-3.3%</b>	<b>(191,085)</b>
Income	4,586	4,613	27	0.6%	18,344	17,147	(1,197)	-6.5%	55,031
Pay	(3,745)	(3,611)	134	3.6%	(14,980)	(13,780)	1,200	8.0%	(44,945)
Non-Pay	(840)	(1,001)	(161)	-19.1%	(3,361)	(3,367)	(6)	-0.2%	(10,086)
<b>R&amp;D</b>	<b>1</b>	<b>0</b>	<b>(1)</b>	<b>-100.0%</b>	<b>2</b>	<b>(0)</b>	<b>(2)</b>	<b>-100.0%</b>	<b>0</b>
<b>Central &amp; Technical</b>	<b>2,351</b>	<b>1,290</b>	<b>(1,061)</b>	<b>-45.1%</b>	<b>12,003</b>	<b>18,847</b>	<b>6,843</b>	<b>57.0%</b>	<b>39,953</b>
<b>Underlying EBITDA</b>	<b>7,123</b>	<b>1,399</b>	<b>(5,724)</b>	<b>-80.4%</b>	<b>14,323</b>	<b>4,060</b>	<b>(10,263)</b>	<b>-71.7%</b>	<b>42,374</b>

Source: Finance Ledger

### MRC

- Income shortfall due to lower than planned activity due to the JR2 refresh (-£0.9m), critical care (-£0.3m) and outpatients (-£1.2m). With higher than planned non-elective activity, reduced by £0.8m due to marginal blended payment.
- Pay overspend from middle grade medical locums. HART underspending due to vacancies (+£0.4m).
- Non-Pay underspend due to unspent growth monies.

### CSS

- Income shortfall due to lower elective and radiology activity (-£0.1m) and radiology pass through devices (-£0.2m) offset by increases in Direct Access.
- Pay and non-pay overspend due to additional spend in radiology (-£0.1m in month) and medical staffing (-£0.3m) as well as undelivered productivity improvements

### SuWOn

- Income shortfall due to pass through drugs (-£0.3m), offset in expenditure. Low Q1 transplant activity (-£0.8m, highest activity in M4) partly offset by Birth coding being improved and brought in line with national standards (+£0.4m)
- Pay overspend due to premium costs of maintaining activity levels through the use of incentive pay rates to support Benign Gynaecology (-£0.45m) and agency staffing (Theatres -£0.4m, Surgery inpatient -£1.1m, other inpatient -£0.9m)
- Non-pay overspend due to costs of insourcing activity provision to maintain capacity in Urology and Surgery (-£0.8m)

### NOTSSCaN

- £0.8m of variance due to worsening from forecast, the basis of budgets, to year end outturn in 18/19.
- Income shortfall due to lower than planned activity due to the JR2 refresh (-£1.8m), Orthopaedic electives (-£0.5m) and changes in non-elective case mix (-£0.8m).
- Pay overspend from premium costs of temporary staffing (-£1.4m) undelivered productivity improvements.
- Non-Pay underspend due to activity shortfall.

### Corporate

- Income shortfall in Education and Estates
- Pay overspend in Education and Corporate, partly offset by vacancies in Estates.
- Income includes released prior year accruals of +£0.6m.

### Central & Technical

- Income includes released prior year accruals of +£5.8m.

# Commissioning: Income Summary

## Split by Point of Delivery

Category £000's	IN MONTH 4			YEAR TO DATE			FULL YEAR
	Plan	Actual	Variance	Plan	Actual	Variance	Plan
Non Elective and Births	20,348	20,261	(87)	80,190	79,585	(606)	240,278
Elective	16,112	15,976	(136)	58,845	55,445	(3,400)	178,597
Outpatient	13,178	13,047	(131)	48,051	47,633	(419)	144,454
Pass through Drugs and Devices	13,411	11,081	(2,330)	46,401	44,775	(1,626)	140,420
Critical Care	4,806	4,585	(221)	18,914	17,544	(1,370)	56,742
Diagnostics	3,697	3,750	53	13,106	13,281	175	40,784
A&E	2,266	2,288	21	8,920	8,869	(50)	26,759
Maternity Pathway	1,397	1,369	(28)	5,497	5,209	(288)	16,490
Radiotherapy	1,167	1,180	12	4,263	4,090	(173)	12,789
Chemotherapy	676	558	(118)	2,467	2,044	(424)	7,402
Other - POD Income	4,998	4,592	(406)	25,457	25,662	205	66,591
Other - Central Adjustments	(981)	(608)	372	(3,922)	(1,711)	2,211	(1,969)
<b>Total Commissioning Income</b>	<b>81,075</b>	<b>78,078</b>	<b>(2,997)</b>	<b>308,189</b>	<b>302,424</b>	<b>(5,764)</b>	<b>929,336</b>

## Key Commissioning Income Values

Key Commissioning Values £000's	YEAR TO DATE	PRIOR MONTH	COMMENT
OCCG: Urgent Care Blended Payment	(768)	(739)	Underperforming
OCCG: Balance to Contract Value	(1,834)	(1,908)	Improved
Prior Year Released Accruals	6,658	5,770	Prior year increase

## Split by Commissioner

Commissioner Split £000's	% of Annual Plan	YEAR TO DATE			PRIOR MONTH	FULL YEAR
		Plan	Actual	Variance		Plan
NHSE Wessex Contract	43%	134,312	131,144	(3,168)	(1,827)	404,106
Assumed income from NHSE Wessex	2%	5,900	0	(5,900)	(3,361)	17,700
<b>NHSE Wessex Total</b>		<b>140,212</b>	<b>131,144</b>	<b>(9,068)</b>	<b>(5,188)</b>	<b>421,806</b>
NHS Oxfordshire CCG	40%	121,672	121,672	0	0	367,858
Assumed income from OCCG	1%	2,244	0	(2,244)	(1,683)	6,731
<b>NHS Oxfordshire CCG Total</b>		<b>123,915</b>	<b>121,672</b>	<b>(2,244)</b>	<b>(1,683)</b>	<b>374,589</b>
Other SLAs & NCA	14%	43,142	42,668	(474)	(451)	130,185
Other income in Divisional Plans	0%	1,012	283	(729)	(1,286)	3,036
<b>Total before Central Adjustments</b>		<b>308,282</b>	<b>295,767</b>	<b>(12,515)</b>	<b>(8,608)</b>	<b>929,616</b>
Central Adjustments		(93)	6,658	6,751	5,840	(280)
<b>Total Commissioning Income</b>		<b>308,189</b>	<b>302,424</b>	<b>(5,764)</b>	<b>(2,768)</b>	<b>929,336</b>

Note that current month data is an estimate and will be refreshed with actual data in future periods

Source: SLAM and Commissioning Income Pack

- Other - Central Adjustments includes the release of prior year accruals following resolution of year end issues (+£6.7m), £1.8m of which is to cover OCCG contract over performance
- Improvement in under performance in elective activity in-month, based on estimates, but no recovery on prior period performance. Lower than planned transplant volumes and lower than planned case mix.
- Improvement in under performance in non elective activity in-month, based on estimates. Still lower than planned non-elective and births overall, but with differential drivers. Lower than planned births, and case mix in specialist surgery, but considerably higher than planned urgent care activity in medicine.
- Lower than planned critical care income.
- Other areas include the backdated correction to chemotherapy drugs billing.
- Significant under performance in Specialised/NHSE (-£9.1m on a cost and volume contract for activity), in elective (-£3.8m), non-elective (-£2.0m), pass through drugs/devices (-£1.6m) and critical care (-£0.9m).
- Over performance in Oxfordshire CCG (+£2.6m on a block contract before adjustment for blended tariff & block), in elective (+£1.1m) and non-elective (+£1.0m).
- Urgent care (A&E and non elective) activity for OCCG has steadied in month
- Central Adjustments includes the release of prior year accruals (+£6.7m).







# Commissioning: Activity Summary

## Split by Point of Delivery

Activity by POD & Main Commissioner	IN MONTH 4		YEAR TO DATE		FULL YEAR
	Actual	Variance	Actual	Variance	Plan
Oxfordshire CCG	11,784	556	45,694	1,507	132,559
NHSE Wessex	0	0	0	0	0
Others	2,335	127	9,080	388	26,076
<b>A&amp;E Total</b>	<b>14,119</b>	<b>683</b>	<b>54,774</b>	<b>1,895</b>	<b>158,635</b>
Oxfordshire CCG	4,818	441	16,564	580	48,544
NHSE Wessex	1,005	(44)	3,799	(33)	11,619
Others	2,010	56	7,147	12	21,598
<b>Day Case Total</b>	<b>7,833</b>	<b>453</b>	<b>27,510</b>	<b>559</b>	<b>81,761</b>
Oxfordshire CCG	679	0	2,580	102	7,470
NHSE Wessex	789	(45)	2,681	(365)	9,269
Others	437	1	1,587	(7)	4,838
<b>Elective Total</b>	<b>1,905</b>	<b>(44)</b>	<b>6,848</b>	<b>(270)</b>	<b>21,577</b>
Oxfordshire CCG	5,729	(222)	23,900	447	70,267
NHSE Wessex	745	(28)	3,011	(32)	9,129
Others	1,146	6	4,415	(77)	13,466
<b>Non Elective Total</b>	<b>7,620</b>	<b>(244)</b>	<b>31,326</b>	<b>338</b>	<b>92,862</b>
Oxfordshire CCG	37,962	1,795	139,036	7,093	397,282
NHSE Wessex	16,960	563	61,691	1,807	179,653
Others	12,468	(802)	46,876	(1,586)	145,581
<b>Outpatient Total</b>	<b>67,390</b>	<b>1,556</b>	<b>247,603</b>	<b>7,314</b>	<b>722,516</b>
Oxfordshire CCG	5,769	(1,312)	21,577	(4,161)	77,571
NHSE Wessex	2,762	330	9,176	295	26,645
Others	1,279	(778)	4,577	(2,866)	22,413
<b>Outpatient Procedures Total</b>	<b>9,810</b>	<b>(1,760)</b>	<b>35,330</b>	<b>(6,732)</b>	<b>126,629</b>
<b>Total Commissioning Activity</b>	<b>108,677</b>	<b>644</b>	<b>403,391</b>	<b>3,104</b>	<b>1,203,979</b>

Note that current month data is an estimate and will be refreshed with actual data in future periods

Source: SLAM and Commissioning Income Pack




- A&E: Considerable increase in attendance volumes; 5.6% YTD above same period in 2018/19
- Non-elective: Increase in volumes seen at the start of the year has flattened, but continues to be challenging; 1% above same period 2018/19
- Elective and day case: Drop in volumes, in particular higher value specialised activity
- Births: Lower than previous years, which is expected to continue, and is being seen nationally
- Outpatient: Increase on previous years, with offset in outpatient procedures, so broadly flat overall

M4 figures are forecast using M3 YTD data; July has significantly more working days than the average of the previous months (23 v 21.6), hence expectation and plan is for an increase in activity in PODs where working days are a factor (largely elective /day case and outpatient activity)



# Pay: Run Rate Overview




- Pay overall remains notably higher than the previous year, adjusting for inflation, as a consequence of steadily increasing substantive pay and continuing trend of increased temporary pay costs to maintain operational capacity.
- Pay is significantly higher than plan, with the planned increase in substantive staff to enable a reduction in high cost agency, yet to impact on spend.

Staff Group	201819	201819	201819	201819	201819	201819	201819	201819	201819	201819	201920	201920	201920	201920
£000's	M4	M5	M6	M7	M8	M9	M10	M11	M12	M1	M2	M3	M4	
<b>Substantive</b>														
Consultants and Medics	(16,532)	(15,964)	(17,736)	(17,228)	(17,257)	(16,647)	(18,020)	(17,323)	(19,125)	(17,942)	(17,660)	(17,545)	(18,982)	
Nurse and Midwives	(12,105)	(12,675)	(12,276)	(12,482)	(12,866)	(12,546)	(12,815)	(12,730)	(13,079)	(13,799)	(13,274)	(13,267)	(13,016)	
Scientific, Thec., Therapeutic	(5,890)	(6,251)	(6,176)	(5,969)	(6,056)	(6,206)	(6,035)	(6,063)	(6,200)	(6,850)	(6,618)	(6,432)	(6,588)	
Health Care Assistants & Support	(4,238)	(4,428)	(4,229)	(4,303)	(4,309)	(4,335)	(4,401)	(4,466)	(4,432)	(4,608)	(4,584)	(4,624)	(4,502)	
Other Staff	(7,287)	(8,016)	(7,635)	(7,743)	(7,622)	(7,435)	(7,872)	(7,747)	(7,760)	(8,124)	(7,944)	(7,870)	(7,894)	
<b>Total Substantive</b>	<b>(46,053)</b>	<b>(47,335)</b>	<b>(48,052)</b>	<b>(47,725)</b>	<b>(48,111)</b>	<b>(47,169)</b>	<b>(49,142)</b>	<b>(48,329)</b>	<b>(50,595)</b>	<b>(51,322)</b>	<b>(50,080)</b>	<b>(49,738)</b>	<b>(50,982)</b>	
<b>Bank</b>														
Consultants and Medics	(478)	(410)	(476)	(541)	(500)	(493)	(609)	(491)	(496)	(613)	(452)	(292)	(524)	
Nurse and Midwives	(1,348)	(1,300)	(1,176)	(1,092)	(1,259)	(1,180)	(1,405)	(1,502)	(1,771)	(1,362)	(1,415)	(1,445)	(1,436)	
Scientific, Thec., Therapeutic	(103)	(131)	(94)	(144)	(153)	(136)	(157)	(155)	(148)	(159)	(171)	(149)	(177)	
Health Care Assistants & Support	(390)	(478)	(648)	(383)	(423)	(435)	(457)	(471)	(579)	(503)	(490)	(495)	(568)	
Other Staff	(249)	(291)	(216)	(251)	(245)	(233)	(261)	(265)	(314)	(244)	(339)	(281)	(380)	
<b>Total Bank</b>	<b>(2,569)</b>	<b>(2,609)</b>	<b>(2,610)</b>	<b>(2,412)</b>	<b>(2,579)</b>	<b>(2,479)</b>	<b>(2,889)</b>	<b>(2,884)</b>	<b>(3,308)</b>	<b>(2,881)</b>	<b>(2,867)</b>	<b>(2,661)</b>	<b>(3,086)</b>	
<b>Agency</b>														
Consultants and Medics	(603)	(485)	(386)	(530)	(522)	(413)	(497)	(468)	(634)	(526)	(664)	(596)	(744)	
Nurse and Midwives	(236)	(336)	(418)	(616)	(670)	(487)	(617)	(557)	(711)	(577)	(670)	(578)	(665)	
Scientific, Thec., Therapeutic	(410)	(367)	(358)	(386)	(371)	(259)	(396)	(330)	(365)	(361)	(419)	(378)	(417)	
Health Care Assistants & Support	(20)	(30)	(19)	(17)	(35)	(45)	(71)	(59)	(81)	(102)	(131)	(151)	(159)	
Other Staff	(123)	(120)	(112)	(169)	(205)	(165)	(199)	(267)	(257)	(224)	(133)	(171)	(248)	
<b>Total Agency</b>	<b>(1,391)</b>	<b>(1,337)</b>	<b>(1,293)</b>	<b>(1,716)</b>	<b>(1,803)</b>	<b>(1,370)</b>	<b>(1,780)</b>	<b>(1,681)</b>	<b>(2,047)</b>	<b>(1,790)</b>	<b>(2,017)</b>	<b>(1,874)</b>	<b>(2,233)</b>	
<b>Total Pay</b>	<b>(50,013)</b>	<b>(51,281)</b>	<b>(51,955)</b>	<b>(51,853)</b>	<b>(52,493)</b>	<b>(51,017)</b>	<b>(53,811)</b>	<b>(52,894)</b>	<b>(55,950)</b>	<b>(55,993)</b>	<b>(54,964)</b>	<b>(54,273)</b>	<b>(56,301)</b>	



## Pay: Temporary Staffing



- Pay on temporary staffing remains notably higher than the previous year, adjusting for inflation, with a year on-year increase of c£1m+ per month.
- Agency spend has been above the ceiling in every month this financial year and in every month, with the exception of December 2018, since October 2018.
- Agency spend in July 2019 is £2.23m – higher than every other month in 2018/19 and 2019/20.

Source: Finance Ledger


## Non Pay: Run Rate Overview

Non-Pay £000's	201819 M4	201819 M5	201819 M6	201819 M7	201819 M8	201819 M9	201819 M10	201819 M11	201819 M12	201920 M1	201920 M2	201920 M3	201920 M4
Clinical Negligence	(2,757)	(2,757)	(1,485)	(2,757)	(2,098)	(2,757)	(2,783)	(2,757)	(2,731)	(2,527)	(2,537)	(2,527)	(2,527)
Clinical Supplies & Services	(8,682)	(7,808)	(7,191)	(8,730)	(8,417)	(8,672)	(8,162)	(7,799)	(7,135)	(8,348)	(7,947)	(7,052)	(8,755)
Drugs (Excl Pass Through)	(180)	1,005	(495)	(639)	(649)	1,003	(339)	(97)	(700)	488	(233)	(424)	(280)
General Supplies & services	(2,731)	(2,133)	(1,997)	(2,118)	(2,187)	(2,116)	(2,093)	(1,495)	(2,032)	(2,153)	(2,019)	(1,912)	(1,979)
Internal Recharges	53	(39)	(99)	74	(18)	6	8	(1)	(7)	(100)	65	35	(0)
Other Expenditure	(3,248)	(4,048)	(4,915)	(3,121)	(4,128)	(4,662)	(4,039)	(4,903)	(12,589)	(2,295)	(2,456)	(4,046)	(3,474)
Passthrough Drugs & Devices	(11,989)	(13,884)	(11,488)	(11,539)	(11,661)	(10,117)	(11,330)	(10,021)	(10,400)	(11,459)	(11,149)	(11,086)	(11,081)
Premises & Fixed plant	(5,330)	(3,849)	(4,542)	(5,393)	(5,104)	(3,581)	(5,091)	(5,667)	(6,807)	(5,067)	(5,605)	(4,739)	(5,511)
<b>Total Non-Pay</b>	<b>(34,865)</b>	<b>(33,513)</b>	<b>(32,212)</b>	<b>(34,224)</b>	<b>(34,262)</b>	<b>(30,896)</b>	<b>(33,828)</b>	<b>(32,740)</b>	<b>(42,401)</b>	<b>(31,461)</b>	<b>(31,881)</b>	<b>(31,750)</b>	<b>(33,606)</b>

Source: Finance Ledger

- Non-Pay costs are +£3.7m better than plan, from unspent growth monies, release of contingency (+£1.3m) and release of prior year accruals (+£0.6m)
- The in month increase in clinical supplies spend is related to increases in activity in areas including Cardiology, JR and west wing theatres and Children's.

## Cash



Note that the forecast reflects updated assumptions on working capital and capital expenditure only.

Source: Finance Ledger

## Capital

Capital Expenditure £m	IN MONTH 4			YEAR TO DATE			FULL YEAR
	Plan	Actual	Variance	Plan	Actual	Variance	Forecast
Medical and Surgical Equipment	0.17	0.01	(0.16)	0.62	2.07	1.46	7.96
Radiology Equipment (excluding leases)	-	-	-	-	-	-	2.00
Operational Estates	0.11	0.10	(0.01)	0.44	0.21	(0.23)	3.35
Gynae Theatre (includes £1.83m PDC funding)	0.53	0.01	(0.51)	1.05	0.05	(1.00)	1.83
Trauma Fire Remedial Works	-	-	-	-	-	-	-
ED Resus Bays	0.73	0.40	(0.33)	1.83	0.87	(0.96)	9.80
Small Schemes	0.02	0.10	0.08	0.06	0.22	0.16	1.00
Information Technology (IT)	0.11	0.85	0.74	0.43	2.32	1.88	6.50
Masterplan	-	-	-	-	-	-	0.50
ACM Cladding	-	-	-	-	-	-	0.77
AICU / Theatres New Build	-	-	-	-	-	-	0.50
Bundled Schemes <£1M	0.32	0.10	(0.22)	1.92	0.86	(1.06)	3.19
Radiotherapy Swindon	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Contingency	0.05	-	(0.05)	0.38	-	(0.38)	1.42
<b>Total Capital Programme Spend</b>	<b>2.02</b>	<b>1.56</b>	<b>(0.46)</b>	<b>6.74</b>	<b>6.60</b>	<b>(0.14)</b>	<b>38.82</b>
PFI Lifecycle	1.18	1.13	(0.05)	4.70	4.50	(0.20)	14.11
Finance Leases	-	-	-	-	-	-	2.00
<b>Technical Capital Adjustments (IFRIC 4 &amp; IFRIC 12)</b>	<b>1.18</b>	<b>1.13</b>	<b>(0.05)</b>	<b>4.70</b>	<b>4.50</b>	<b>(0.20)</b>	<b>16.11</b>
<b>Gross Capital Spend</b>	<b>3.20</b>	<b>2.68</b>	<b>(0.51)</b>	<b>11.44</b>	<b>11.11</b>	<b>(0.33)</b>	<b>54.93</b>
Less Disposals/other deductions	-	-	-	-	-	-	(3.90)
<b>Charge after disposals/other deductions</b>	<b>3.20</b>	<b>2.68</b>	<b>(0.51)</b>	<b>11.44</b>	<b>11.11</b>	<b>(0.33)</b>	<b>51.03</b>
Less Donations/grants received	(0.05)	-	0.05	(0.30)	(0.16)	0.14	(1.55)
Less PFI Capital (IFRIC 12)	(1.18)	(1.13)	0.05	(4.70)	(4.50)	0.20	(14.11)
<b>Planning Shortfall against Control Total</b>	<b>(0.17)</b>	<b>-</b>	<b>0.17</b>	<b>(0.45)</b>	<b>-</b>	<b>0.45</b>	<b>-</b>
<b>Control Total</b>	<b>1.80</b>	<b>1.56</b>	<b>(0.24)</b>	<b>5.99</b>	<b>6.44</b>	<b>0.45</b>	<b>35.37</b>
Reverse Planning Shortfall	0.17	-	(0.17)	0.45	-	(0.45)	-
Plus PFI Residual Interest	0.38	0.38	-	1.51	1.51	-	4.52
Purchase of Financial Assets	-	-	-	1.99	1.99	-	5.89
<b>Total CDEL</b>	<b>2.35</b>	<b>1.93</b>	<b>(0.41)</b>	<b>9.94</b>	<b>9.94</b>	<b>0.00</b>	<b>45.78</b>

Note that the plan above reflects the impact of a 20% reduction in capital spend as agreed by the Board in July. The Trust is awaiting formal correspondence reversing this decision following public announcements.

Source: Finance Ledger

Cash balance as at the end of July was £72.8m, £14.0m higher than plan.

- +£13.2m higher than expected payables, largely due to timing since the payment run on 1 August was £14m
- +£7.7m lower receivables due to fewer commissioning income accruals than expected and some receipts from debtors with large/overdue balances
- +£3.4m better 18/19 cash outturn than plan start point
- +£0.4m delay in OUC cash outflow
- -£0.9m delay in drawdown of cash to support capital programme
- -£9.3m operating deficit

Gross capital spend is £0.3m lower than plan, from:

- +£1.9m higher spend in Information Technology (IT), due to profiling.
- +£1.5m higher spend in Medical & Surgical Equipment, from delayed 18/19 spend and accelerated purchases
- -£1.1m lower spend in Bundled Schemes (<£1m), due to in-year slippage on schemes
- -£1.0m lower spend on Gynae Theatre, due to delay in finalizing PDC funding
- -£1.0m lower spend in ED Resus, due to in-year slippage

## Statement of Financial Position (SOFP)

Statement of Financial Position £000s	MONTH 12 2018/19	MONTH 2 2019/20	MONTH 3 2019/20	MONTH 4 2019/20	IN MONTH Movement	YEAR TO DATE Movement
<b>Non Current Assets:</b>						
Property, Plant and Equipment	513,196	514,860	511,079	511,443	364	(1,753)
Intangible Assets	10,662	10,397	10,252	10,208	(44)	(454)
Investment Property	18,135	18,135	25,535	25,535	0	7,400
Other Investments	15,511	16,965	16,965	17,098	133	1,587
Trade and Other Receivables	6,076	5,537	5,389	5,288	(101)	(788)
<b>Total Non Current Assets</b>	<b>563,580</b>	<b>565,894</b>	<b>569,220</b>	<b>569,572</b>	<b>352</b>	<b>5,992</b>
<b>Current Assets:</b>						
Inventories	23,890	23,711	24,056	24,288	232	398
Trade and Other Receivables	64,050	71,089	74,987	62,799	(12,188)	(1,251)
Other Current Assets	181	151	136	121	(15)	(60)
Cash and Cash Equivalents	53,001	38,011	39,654	72,778	33,124	19,777
<b>Total Current Assets</b>	<b>141,122</b>	<b>132,962</b>	<b>138,833</b>	<b>159,886</b>	<b>21,153</b>	<b>18,864</b>
<b>Total ASSETS</b>	<b>704,702</b>	<b>698,856</b>	<b>708,053</b>	<b>729,558</b>	<b>21,505</b>	<b>24,856</b>
<b>Current Liabilities:</b>						
Trade and Other Payables	(120,009)	(120,886)	(124,176)	(147,793)	(23,617)	(27,784)
Provisions	(3,702)	(3,703)	(3,703)	(3,647)	56	55
Borrowings	(3,027)	(3,357)	(3,666)	(3,933)	(267)	(906)
Commercial Loans	(328)	(381)	(328)	(354)	(26)	(26)
<b>Total Current Liabilities</b>	<b>(127,066)</b>	<b>(128,327)</b>	<b>(131,873)</b>	<b>(155,727)</b>	<b>(23,854)</b>	<b>(28,661)</b>
<b>Net Current Assets/(Liabilities)</b>	<b>14,056</b>	<b>4,635</b>	<b>6,960</b>	<b>4,259</b>	<b>(2,701)</b>	<b>(9,797)</b>
<b>Total Assets Less Current Liabilities</b>	<b>577,636</b>	<b>570,529</b>	<b>576,180</b>	<b>573,831</b>	<b>(2,349)</b>	<b>(3,805)</b>
<b>Non Current Liabilities:</b>						
Trade and Other Payables	(3,146)	(3,132)	(3,125)	(3,118)	7	28
Provisions	(2,675)	(2,675)	(2,675)	(2,675)	0	0
Borrowings	(244,327)	(243,323)	(242,778)	(242,274)	504	2,053
Commercial Loans	(7,273)	(7,273)	(7,193)	(7,193)	0	80
<b>Total Non Current Liabilities</b>	<b>(257,421)</b>	<b>(256,403)</b>	<b>(255,771)</b>	<b>(255,260)</b>	<b>511</b>	<b>2,161</b>
<b>Assets Less Liabilities (Total Assets Employed)</b>	<b>320,215</b>	<b>314,126</b>	<b>320,409</b>	<b>318,571</b>	<b>(1,838)</b>	<b>(1,644)</b>
<b>Taxpayers Equity:</b>						
Public Dividend Capital	227,037	227,037	227,037	227,037	0	0
Retained Earnings reserve	(13,655)	(19,738)	(13,454)	(15,291)	(1,837)	(1,636)
Revaluation Reserve	104,977	104,971	104,970	104,969	(1)	(8)
Other Reserves	1,743	1,743	1,743	1,743	0	0
FV Assets Reserve	113	113	113	113	0	0
<b>Total Taxpayers Equity</b>	<b>320,215</b>	<b>314,126</b>	<b>320,409</b>	<b>318,571</b>	<b>(1,838)</b>	<b>(1,644)</b>
<b>Working Capital Metrics</b>						
Trade Debtors Days	13.5	12.0	10.5	10.0	(0.5)	(3.5)
Trade Payables Days	52.2	38.6	41.7	47.5	5.7	(4.7)

Source: Finance Ledger

### Non Current Assets

- Non-Current assets have increased by +£6.0m to date, due to the revaluation of property, including reclassification from property, plant and equipment to investment property.

### Current Assets

- Current assets have increased by +£18.9m to date, due to the receipt of quarterly education funding in advance and quarterly MRET funding in advance. There was also a significant increase in accrued income within the clinical divisions this month.

### Current Liabilities

- Current liabilities have increased by -£28.7m to date, partly due to the significant commissioning income underperformance issues on the specialist contract and partly due to accounts payables timing as the first payment run on 1 August was £14m

### Non Current Liabilities

- Non current liabilities have reduced by +£2.2m to date, due to repayment of PFI borrowings as planned.